Carmel, IN, United States of America

Liandong Ma

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Liandong Ma. Retrieved from https://idiyas.com/inventor/liandong-ma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Liandong Ma

Introduction

Liandong Ma is an accomplished inventor based in Carmel, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target serious health conditions.

Latest Patents

Liandong Ma holds 1 patent for an amino pyrazole compound. This invention provides amino pyrazole compounds that are useful in the treatment of chronic myeloproliferative disorders and various cancers, including glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.

Career Highlights

Liandong Ma is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work focuses on innovative solutions that address critical health challenges.

Collaborations

Some of his notable coworkers include Timothy Paul Burkholder and Joshua Ryan Clayton, who contribute to the collaborative environment at Eli Lilly and Company.

Conclusion

Liandong Ma's contributions to the field of medicine through his innovative patent demonstrate his commitment to improving health outcomes for patients facing serious diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…